| abstract |
The human antibody or the antigen-binding portion of the human antibody that specifically binds or inhibits the hPCSK9 enzyme has the ability to reduce LDL cholesterol by 40-80%, for a period of at least 24, 60 or 90 days, depending on the pre-dose level, with little or no effect reduction. No significant HDL-cholesterol level and/or little or no effect on liver function, as determined by aspartate and alanine-stimulating enzyme measurements. |